Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
Werte in diesem Artikel
Conference Call and Webcast to Follow
WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2023 on Wednesday, February 7, 2024, after the market closes.
Vanda will host a conference call at 4:30 PM ET on Wednesday, February 7, 2024, during which management will discuss the fourth quarter and full year 2023 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 8053170.
The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Wednesday, February 7, 2024, beginning at 8:30 PM ET and will be accessible until Wednesday, February 14, 2024, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 8053170.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2023-financial-results-on-february-7-2024-302049731.html
SOURCE Vanda Pharmaceuticals Inc.
Ausgewählte Hebelprodukte auf Vanda Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Vanda Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Vanda Pharmaceuticals Aktie News
Vanda Pharmaceuticals Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Vanda Pharmaceuticals nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 11.12.18 | Vanda Pharmaceuticals Perform | Oppenheimer & Co. Inc. | |
| 04.12.18 | Vanda Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 21.09.18 | Vanda Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
| 19.01.18 | Vanda Pharmaceuticals Buy | Seaport Global Securities | |
| 26.05.17 | Vanda Pharmaceuticals Buy | H.C. Wainwright & Co. |
